Jazz Pharmaceuticals (JAZZ) News Today

Renaissance Technologies LLC reduced its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 12.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,025,868 shares of the specialty pharmaceutical compan

Thompson Siegel & Walmsley LLC raised its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 30.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 721,530 shares of the s

Texas Permanent School Fund Corp raised its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 10.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 60,955 shares of the specialty

Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) SVP Mary Elizabeth Henderson sold 1,410 shares of Jazz Pharmaceuticals stock in a transaction on Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the transaction, the senior vice president now directly owns 14,531 shares of the company's stock, valued at $1,573,707.30. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Needham & Company LLC reiterated a "buy" rating and set a $205.00 price target on shares of Jazz Pharmaceuticals in a report on Tuesday.

Cantor Fitzgerald reaffirmed an "overweight" rating and set a $140.00 price target on shares of Jazz Pharmaceuticals in a research note on Monday.

Rhumbline Advisers lowered its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 8.4% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 169,400 shares of the specialty pharmaceutical company's stock after

LSV Asset Management raised its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 4.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,480,563 shares of the specialty pharmaceutical company's

Jazz Pharmaceuticals (NASDAQ:JAZZ) Sees Large Volume Increase

Zurcher Kantonalbank Zurich Cantonalbank cut its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 74.3% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,170 shares of the specialty pharmaceutica

Principal Financial Group Inc. lessened its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 11.7% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 209,759 shares of the specialty pharmaceutical company's stock after

Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) saw a significant decline in short interest in the month of August. As of August 15th, there was short interest totalling 2,040,000 shares, a decline of 10.9% from the July 31st total of 2,290,000 shares. Based on an average daily volume of 734,200 shares, the short-interest ratio is currently 2.8 days. Currently, 3.4% of the shares of the company are sold short.

Bank of New York Mellon Corp trimmed its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 8.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 512,813 shares of the specialty pharmac

BNP PARIBAS ASSET MANAGEMENT Holding S.A. lessened its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 8.2% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 438,211 shares of the specialty pharmaceutical company's

Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) have been given an average rating of "Moderate Buy" by the fifteen research firms that are currently covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold rating and eleven have give

State of Michigan Retirement System cut its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 14.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,204 shares of the specialty ph

Patriot Financial Group Insurance Agency LLC lowered its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 42.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,308 shares of the specialty pharmaceut

AlphaCentric Advisors LLC increased its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 29.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 11,000 shares of the specialty pharmaceutical company's stock after buying an additi

Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) - Investment analysts at Zacks Research boosted their Q3 2024 earnings per share (EPS) estimates for shares of Jazz Pharmaceuticals in a research report issued on Wednesday, August 21st. Zacks Research analyst S. Ganoria now anticipates that th

Jazz Pharmaceuticals (NASDAQ:JAZZ) Shares Down 1.4%